Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma (Q36251337)

13 August 2017

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma (English)

1 reference

13 August 2017

1 reference

Motoo Nagane

1

1 reference

13 August 2017

Ryo Nishikawa

2

1 reference

13 August 2017

Yoshitaka Narita

3

1 reference

13 August 2017

Hiroyuki Kobayashi

4

1 reference

13 August 2017

Shingo Takano

5

1 reference

13 August 2017

Nobusada Shinoura

6

1 reference

13 August 2017

Tomokazu Aoki

7

1 reference

13 August 2017

Kazuhiko Sugiyama

8

1 reference

13 August 2017

Junichi Kuratsu

9

1 reference

13 August 2017

Yoshihiro Muragaki

10

1 reference

13 August 2017

Yutaka Sawamura

11

1 reference

13 August 2017

Masao Matsutani

12

1 reference

13 August 2017

27 July 2012

1 reference

Japanese Journal of Clinical Oncology

13 August 2017

1 reference

13 August 2017

42

1 reference

13 August 2017

10

1 reference

13 August 2017

887-895

1 reference

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Recurrent glioblastoma multiforme: a review of natural history and management options

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Epidemiology of brain tumors.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

ACNU-based chemotherapy for recurrent glioma in the temozolomide era.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Response criteria for phase II studies of supratentorial malignant glioma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448378

Management of malignant glioma: steady progress with multimodal approaches

22 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS121

Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS121

Expression of VEGF and its receptors in different brain tumors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22844129

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JJCO/HYS121

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

22844129

1 reference